

# Stefania Butini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6449117/publications.pdf>

Version: 2024-02-01

143  
papers

4,229  
citations

87886

38  
h-index

168376

53  
g-index

150  
all docs

150  
docs citations

150  
times ranked

5413  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant <i>P. falciparum</i> strains. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5384-5388.	2.2	142
2	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 151, 4-34.	5.7	128
3	Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT <sub>3</sub> Receptor Agonists: Synthesis, Further Structure-Activity Relationships, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4362-4379.	6.4	103
4	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D <sub>3</sub> Receptor Ligands: Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D <sub>3</sub> /D <sub>2</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3822-3839.	6.4	90
5	Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 864-879.	5.5	80
6	Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D <sub>3</sub> and Serotonin 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> Receptors: Design, Synthesis, and Effects on Behavior. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 151-169.	6.4	79
7	Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13466-13513.	6.4	75
8	Design, Synthesis, and Structure-Activity Relationship Studies of 4-Quinoliny- and 9-Acrydinylhydrazones as Potent Antimalarial Agents. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1333-1343.	6.4	73
9	Specific Targeting of Hepatitis C Virus NS3 RNA Helicase. Discovery of the Potent and Selective Competitive Nucleotide-Mimicking Inhibitor QU663. <i>Biochemistry</i> , 2005, 44, 9637-9644.	2.5	71
10	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2612-2632.	6.4	70
11	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 23-39.	6.4	69
12	Dopamine D <sub>3</sub> Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. <i>Frontiers in Neuroscience</i> , 2016, 10, 451.	2.8	66
13	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1919-1929.	6.4	65
14	Pyrrolo[1,3]benzothiazepine-Based Serotonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structure-Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 143-157.	6.4	60
15	Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10387-10404.	6.4	58
16	Structure-based discovery of the first non-covalent inhibitors of <i>Leishmania major</i> trypanothione peroxidase by high throughput docking. <i>Scientific Reports</i> , 2015, 5, 9705.	3.3	58
17	Polypharmacology of dopamine receptor ligands. <i>Progress in Neurobiology</i> , 2016, 142, 68-103.	5.7	57
18	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3154-3170.	6.4	56

#	ARTICLE	IF	CITATIONS
19	Combining 4-Aminoquinoline- and Clotrimazole-Based Pharmacophores toward Innovative and Potent Hybrid Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 502-513.	6.4	55
20	Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4367-4377.	6.4	53
21	Computational Tool for Fast in silico Evaluation of hERG K <sup>+</sup> Channel Affinity. <i>Frontiers in Chemistry</i> , 2017, 5, 7.	3.6	52
22	Disease-Modifying Anti-Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with Amyloid Aggregation. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 624-632.	3.9	51
23	Discovery of Huperzine A-Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3421-3425.	6.4	50
24	Development of antitubercular compounds based on a 4-quinolylylhydrazone scaffold. Further structure-activity relationship studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6063-6072.	3.0	50
25	Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. <i>Medicinal Research Reviews</i> , 2020, 40, 1002-1060.	10.5	49
26	Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases. <i>Current Pharmaceutical Design</i> , 2003, 9, 599-625.	1.9	47
27	Targeting Dopamine D <sub>3</sub> and Serotonin 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9578-9597.	6.4	46
28	Clotrimazole Scaffold as an Innovative Pharmacophore Towards Potent Antimalarial Agents: Design, Synthesis, and Biological and Structure-Activity Relationship Studies. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1278-1294.	6.4	45
29	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 5137.	2.8	44
30	Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7153-7165.	6.4	43
31	Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure-Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6948-6967.	6.4	43
32	Development of Potent Inhibitors of the <i>Mycobacterium tuberculosis</i> Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. <i>ChemMedChem</i> , 2018, 13, 422-430.	3.2	43
33	Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues. <i>Journal of Organic Chemistry</i> , 2010, 75, 2333-2340.	3.2	42
34	A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. <i>Journal of Molecular Medicine</i> , 2008, 86, 457-469.	3.9	41
35	Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold: Exploring an Innovative Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 595-598.	6.4	40
36	Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1178-1182.	2.8	40

#	ARTICLE	IF	CITATIONS
37	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. <i>MedChemComm</i> , 2015, 6, 357-362.	3.4	39
38	Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. <i>Frontiers in Neuroscience</i> , 2016, 10, 201.	2.8	39
39	Identification of novel fluorescent probes preventing PrP Sc replication in prion diseases. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 859-873.	5.5	39
40	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 127-138.	5.5	39
41	The Structural Evolution of $\beta$ -Secretase Inhibitors: A Focus on the Development of Small-Molecule Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1787-1807.	2.1	39
42	Specific Targeting of Peripheral Serotonin 5-HT <sub>3</sub> Receptors. Synthesis, Biological Investigation, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3548-3562.	6.4	38
43	Rational design of the first difluorostatone-based PfSUB1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3582-3586.	2.2	38
44	The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. <i>Scientific Reports</i> , 2017, 7, 11152.	3.3	38
45	Novel Atypical Antipsychotic Agents: A Rational Design, an Efficient Palladium-Catalyzed Route, and Pharmacological Studies. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1705-1708.	6.4	37
46	Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structure-Activity Relationship, Molecular Modeling, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 344-359.	6.4	36
47	Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats. <i>Neuropsychopharmacology</i> , 2016, 41, 1329-1339.	5.4	36
48	iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated $\alpha$ -tubulin defect which improves after iHDAC6 treatment in Rett syndrome. <i>Experimental Cell Research</i> , 2018, 368, 225-235.	2.6	36
49	Novel, Potent, and Selective Quinoxaline-Based 5-HT <sub>3</sub> Receptor Ligands. 1. Further Structure-Activity Relationships and Pharmacological Characterization. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6946-6950.	6.4	35
50	Structural characterization of <i>Giardia duodenalis</i> thioredoxin reductase (g TrxR) and computational analysis of its interaction with NBDHEX. <i>European Journal of Medicinal Chemistry</i> , 2017, 135, 479-490.	5.5	35
51	A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. <i>Molecules</i> , 2019, 24, 4373.	3.8	34
52	First dual AK/GSK-3 $\beta$ inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 438-457.	5.5	33
53	Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors. <i>ACS Chemical Biology</i> , 2018, 13, 2406-2413.	3.4	33
54	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 433-457.	2.1	33

#	ARTICLE	IF	CITATIONS
55	Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6898-6915.	6.4	32
56	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. <i>Frontiers in Chemistry</i> , 2019, 7, 574.	3.6	32
57	The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2009, 69, 8366-8375.	0.9	31
58	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 290-320.	5.5	31
59	Quinolyldrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5317-5321.	2.2	28
60	Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 85-94.	5.5	28
61	Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. <i>Drug Discovery Today</i> , 2019, 24, 1370-1388.	6.4	28
62	An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds. <i>Journal of Organic Chemistry</i> , 2008, 73, 8458-8468.	3.2	27
63	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1401-1420.	6.4	27
64	PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. <i>British Journal of Cancer</i> , 2011, 104, 281-289.	6.4	27
65	Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 698-718.	5.5	27
66	Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 228-236.	2.8	27
67	Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5213-5216.	2.2	26
68	Development of novel cyclic peptides as pro-apoptotic agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 117, 301-320.	5.5	26
69	Screening and Phenotypical Characterization of <i>Schistosoma mansoni</i> Histone Deacetylase 8 (HDAC8) Inhibitors as Multistage Antischistosomal Agents. <i>ACS Infectious Diseases</i> , 2020, 6, 100-113.	3.8	26
70	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9960-9988.	6.4	26
71	Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4803-4807.	6.4	25
72	Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5949-5953.	6.4	25

#	ARTICLE	IF	CITATIONS
73	Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials. <i>Tetrahedron Letters</i> , 2009, 50, 5719-5722.	1.4	24
74	Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2268-2276.	2.8	23
75	1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6614-6618.	6.4	22
76	The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , 2016, 49, 74-88.	3.3	22
77	Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 112998.	5.5	22
78	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. <i>Medicinal Chemistry</i> , 2019, 15, 755-770.	1.5	22
79	Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1 <i>H</i> -Cyclopentapyrimidin-2,4(1 <i>H</i> ,3 <i>H</i> )-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4793-4805.	6.4	21
80	Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. <i>Cells</i> , 2022, 11, 471.	4.1	21
81	Microwave-assisted synthesis of 4-quinolylylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives. <i>Tetrahedron Letters</i> , 2008, 49, 2074-2077.	1.4	20
82	Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. <i>Cancer Biology and Therapy</i> , 2016, 17, 849-858.	3.4	20
83	( <i>S</i> )-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2124-2130.	6.4	20
84	The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. <i>Biochemical Pharmacology</i> , 2014, 87, 611-624.	4.4	19
85	Targeting clinically-relevant metallo- $\beta$ -lactamases: from high-throughput docking to broad-spectrum inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 98-109.	5.2	19
86	Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. <i>Future Medicinal Chemistry</i> , 2016, 8, 1573-1587.	2.3	19
87	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. <i>ChemMedChem</i> , 2018, 13, 2090-2103.	3.2	19
88	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. <i>RSC Advances</i> , 2016, 6, 64651-64664.	3.6	19
89	Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant <i>P. falciparum</i> strains. Synthesis and molecular modeling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3535-3539.	2.2	18
90	A stereoselective approach to peptidomimetic BACE1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 233-247.	5.5	17

#	ARTICLE	IF	CITATIONS
91	In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2016, 64, 121-130.	2.4	17
92	Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases. <i>Molecules</i> , 2022, 27, 2561.	3.8	17
93	The Interactions of the 5-HT <sub>3</sub> Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 504-526.	2.1	16
94	A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring. <i>Tetrahedron</i> , 2003, 59, 87-93.	1.9	15
95	Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1224-1228.	6.4	15
96	Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 85-89.	2.2	15
97	Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 492-495.	2.2	15
98	Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. <i>RSC Advances</i> , 2015, 5, 22431-22448.	3.6	15
99	Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5412-5418.	2.2	15
100	Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2776-2779.	2.2	14
101	Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111674.	5.5	14
102	Malaria Chemotherapy: Recent Advances in Drug Development. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2010, 5, 195-225.	0.8	13
103	From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. <i>RSC Advances</i> , 2014, 4, 4769-4781.	3.6	13
104	Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines. <i>Journal of Cancer</i> , 2016, 7, 2367-2377.	2.5	13
105	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. <i>ChemMedChem</i> , 2017, 12, 2074-2085.	3.2	13
106	Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). <i>Bioorganic Chemistry</i> , 2019, 89, 103020.	4.1	13
107	Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1716-1736.	3.5	12
108	Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 648-658.	2.4	12

#	ARTICLE	IF	CITATIONS
109	The Ca <sup>2+</sup> -ATPase (SERCA1) Is Inhibited by 4-Aminoquinoline Derivatives through Interference with Catalytic Activation by Ca <sup>2+</sup> , Whereas the ATPase E2 State Remains Functional. <i>Journal of Biological Chemistry</i> , 2011, 286, 38383-38389.	3.4	11
110	A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues. <i>Tetrahedron Letters</i> , 2013, 54, 5387-5390.	1.4	11
111	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114409.	5.5	11
112	The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.4	10
113	A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides. <i>Tetrahedron Letters</i> , 2013, 54, 1233-1235.	1.4	10
114	Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 102, 648-660.	5.5	10
115	Dealing with schistosomiasis: Current drug discovery strategies. <i>Annual Reports in Medicinal Chemistry</i> , 2019, 53, 107-138.	0.9	10
116	Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2173-2191.	3.5	10
117	Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity. <i>Molecules</i> , 2022, 27, 463.	3.8	10
118	Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines. <i>Molecular Medicine Reports</i> , 2015, 12, 3748-3754.	2.4	8
119	Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1791-1800.	3.5	8
120	HCV-targeted Antivirals: Current Status and Future Challenges. <i>Current Pharmaceutical Design</i> , 2014, 20, 3445-3464.	1.9	8
121	Polycondensed heterocycles. Part 12: An approach to the synthesis of 2-acetyl-1- $\epsilon$ -methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4- $\epsilon$ -pyrrolidine]-2- $\epsilon$ -one. <i>Tetrahedron</i> , 2002, 58, 3689-3692.	1.9	7
122	Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells. <i>Investigational New Drugs</i> , 2016, 34, 663-676.	2.6	7
123	A light in the dark: state of the art and perspectives in optogenetics and optopharmacology for restoring vision. <i>Future Medicinal Chemistry</i> , 2019, 11, 463-487.	2.3	7
124	Extra Virgin Olive Oil Extracts of Indigenous Southern Tuscany Cultivar Act as Anti-Inflammatory and Vasorelaxant Nutraceuticals. <i>Antioxidants</i> , 2022, 11, 437.	5.1	7
125	Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 425-448.	5.0	6
126	Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the $\alpha$ -primer grip-region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. <i>Biochemical Pharmacology</i> , 2008, 76, 156-168.	4.4	6



#	ARTICLE	IF	CITATIONS
127	Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors. <i>Chemical Biology and Drug Design</i> , 2016, 87, 112-120.	3.2	6
128	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy. <i>European Journal of Medicinal Chemistry</i> , 2022, 235, 114274.	5.5	6
129	Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs. <i>Tetrahedron Letters</i> , 2016, 57, 920-923.	1.4	5
130	The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. <i>Investigational New Drugs</i> , 2016, 34, 159-167.	2.6	5
131	A Jovic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents. <i>Tetrahedron Letters</i> , 2018, 59, 4466-4470.	1.4	5
132	Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113227.	5.5	5
133	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3935-3938.	2.2	4
134	A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds. <i>Scientific Reports</i> , 2021, 11, 14069.	3.3	4
135	Design and Synthesis of New Oligopeptidic Parvulin Inhibitors. <i>ChemMedChem</i> , 2022, , .	3.2	3
136	Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 1441.	4.1	3
137	In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). <i>Computation</i> , 2022, 10, 69.	2.0	3
138	A Straightforward Approach for Engineering Efficacy and Selectivity at GPCRs. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6687-6688.	6.4	1
139	831: Induction of apoptosis by pyrrolo-1,5-benzoxazepines in oral squamous carcinoma cells. <i>European Journal of Cancer</i> , 2014, 50, S201.	2.8	1
140	Synthetic studies toward bicyclic endoperoxides presenting polar side chains. <i>Tetrahedron Letters</i> , 2018, 59, 4330-4333.	1.4	1
141	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E $\mu$ /4-TCL1 mice through the JNK/STAT4/p66Shc axis. <i>Pharmacological Research</i> , 2021, 174, 105965.	7.1	1
142	Polycondensed Heterocycles. Part 12. An Approach to the Synthesis of 2-Acetyl-1-methyl-1,2,3,4-tetrahydrospiro [isoquinoline-1,4-pyrrolidine]-2-one.. <i>ChemInform</i> , 2002, 33, 154-1	0.0	0
143	Inhibition of SERCA1 by a Novel Antimalarial Compound. <i>Biophysical Journal</i> , 2010, 98, 505a.	0.5	0